VEGFA and breast cancer: The recombinant monoclonal antibody bevacizumab is currently the most widely used and developed antiangiogenic drug in the treatment of BC, able to recognize all the isoforms of VEGF‐A, preventing its binding to the cellular receptor, and inhibiting the angiogenic and proliferative signal.